Professor Glenn Marshall AM
HEAD OF TRANSLATIONAL RESEARCH
MBBS, MD UNSW, FRACP Head of Translational Research and Molecular Carcinogenesis
Professor Glenn Marshall has been Head of the Molecular Carcinogenesis Program at Children’s Cancer Institute since 1995. He is also Clinical Director of the Zero Childhood Cancer personalised medicine program, Paediatric Oncologist at Kids Cancer Centre, and Head of Translational Research at Children’s Cancer Institute.
Professor Marshall has published more than 160 original research articles on various biological and clinical aspects of child cancer. His primary preclinical research interests include the development of Myc and MycN inhibitor drugs, novel histone deacetylase inhibitor therapies, mechanisms by which normal embryonal cells become cancerous, and preventative therapies for embryonal cancer. Glenn has a longstanding clinical and translational research focus on relapse detection by Minimal Residual Disease (MRD) testing in leukaemia, and the therapy of high-risk or relapsed leukaemia.
In addition to his research activities, Glenn is a full-time paediatric haematologist and oncologist in the Kids Cancer Centre at Sydney Children's Hospital, Randwick. He is also a conjoint Professor, School of Women and Children’s Health, Faculty of Medicine at UNSW Sydney and the Director of the Chronic Illness in Childhood academic stream of SPHERE, the Sydney Partnership for Health, Education, Research and Enterprise with UNSW Sydney. In 2011, he was appointed Head of Translational Research at Children’s Cancer Institute. He is the founding Director of the Kids Cancer Alliance, a translational cancer research network of all clinicians and scientists working on child cancer in NSW. This network incorporates the state's three children's medical research institutes (Children's Medical Research Institute, Children's Cancer Institute, Kids Research Institute) and three child cancer centres in a framework which has accelerated translation of laboratory discovery into the clinic.
With colleagues Professors Haber and Norris, he received the NSW Premier’s Award for Excellence in Translational Cancer Research and the NHMRC 'Ten of the Best' award in 2012. He was profiled in The Lancet in 2013 as a successful clinician-scientist. In 2014, Prof Marshall was awarded an Order of Australia (AM) for significant service to medicine in the field of paediatric oncology. In 2017, he was made a Fellow of the Australian Academy of Health and Medical Sciences.